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FIVE-FLUOROURACIL (5FU) is a member of a series of fluorinated pyrimidines
first synthesized in 1957 separately by Heidelberger ofthe University ofWisconsin
and by Duschinsky and Pleven of Hoffmann-LaRoche. Since then it has been
subjected to extensive studies, experimental as well as clinical, as an anti-neo-
plastic agent. It is believed to exert its effect through an irreversible inhibition
ofthe enzyme, thymidylate synthetase, thus blocking the methylation reaction of
deoxyuridilic acid to thymidylic acid. This in turn interferes with the synthesis
of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and produces a
disturbance of growth leading eventually to the death of the cell.
A survey of the current literature revealed that with the exception of a few
adverse reports of considerable toxicity, high lethal rate, and minimal benefit
(Gold, Hall, Shnider, Selawry, Colsky, Owens, Dederick, Holland, Brindley and
Jones, 1959) the overwhelming majority of the reports were favourable, particu-
larly in the palliative treatment of carcinoma ofthe colon, rectum, breast, urinary
bladder and ovary (Curreri, Ansfield, McIver, Weisman and Heidelberger, 1958;
Deren and Wilson, 1960; Wilson, 1960; Hurley and Ellison, 1960; Hurley,
Ellison, Riesch and Schulte, 1960; Hurley, Trump, Flatley and Riesch, 1961;
Zubrod, 1961; Kennedy and Theologides, 1961; Weiss, Jackson and Carabasi,
1961; Schell and Cressy, 1962; Ansfield, Schroeder and Curreri, 1962). All these
workers, however, took notice of the toxic effects of 5FU, and cautioned that it
should only be used under the strictest supervision if large doses were prescribed
as in the palliative treatment of advanced solid cancers. As these reports refer
to the use of the drug largely in European patients it was felt that a clinical trial
should be mounted here in Hong Kong to study not only the efficacy of the drug
in the palliation of advanced cancer but also the response of Chinese patients to
the drug before considering it for wider use, as it is known that patients may vary
in their response to drugs because of genetic as well as acquired factors.
Case material
During a period of 13 months, dating from November 1, 1961 to November 30,
1962, a total of 28 Chinese patients consisting of 23 females and 5 males with ages
ranging from 28 to 75 suffering from various types of advanced solid cancers were
treated with 5FU at the Queen Mary and the Tung Wah Hospitals, Hong Kong.
The number of courses of the drug given to each of them varied from one to five,
and the follow-up period ranged from 2 to 13 months after the completion of the
first course. At the beginning of the clinical trial 2 patients had been given only
about one-third of what we would consider now to be an adequate dose, while
2 others died within 10 days from the commencement of treatment. These 4
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cases have, therefore, been excluded from the analysis. Four patients received
5FU as an adjunct to radiotherapy. The responses of the various neoplasms to
5FU treatment whether given alone or in conjunction with radiotherapy are
shown in Table I.
TABLE I.-Summary ofRes8ilts
Evaluable
A -- Not evaluable
Total Response
number r A Died withinInadequate
Neoplasm of cases Subjective Objective Failure 10 days treatment
Carcinoma of breast . 8 . 5 3 - -
Carcinoma of cervix uteri . 5 . 1 1 3
Carcinoma ofurinary bladder. 3 . 1* 2
Carcinoma of corpus uteri . 2 . 1 it
Carcinoma of ovary 2 . 1 . 1
Carcinoma of kidney . . 2 . 1* 1
Carcinoma of nasopharynx . 1 1
Carcinoma of nasal cavity . 1 1**
Carcinoma offallopian tube . 1 . 1
Carcinoma of rectum . . 1 . 1*
Anaplastic carcinoma of un- 1 . I- 1
known primary
Retroperitoneal sarcoma 1 I 1
Total. . . . 28 . 2 12 10 . 2 2
* 5FU plus deep X-ray therapy.
t 5FU used in combination with deep X-ray therapy, but lesions not covered by radiotherapy also
showed marked regression.
** Patient died 2 weeks following completion oftreatment, hence strictly not evaluable.
Method of treatment
5FU was administered according to the dose schedule recommended by Curreri
et al. (1958). As the oral compound was not available to us, the drug was given
solely by the intravenous route. A course consisted of giving initially a daily
dose of 15 mg. per kilogramme of body weight for 5 consecutive days. This was
followed by a rest of 2 days after which 5FU was again administered but at a
dose of 7-5 mg. per kilogramme of body weight every other day until mild toxic
symptoms appeared or a total of 5 more doses had been given. If mild toxic
symptoms appeared without any sign of tumour regression, our initial policy was
to stop the medication and resume it after the subsidence ofthese symptoms with
the same alternate dailyinjections. However, as we had not observed any tumour
regression following this regime in 7 patients our later policy was to discontinue
treatment if there was no response to the initial course. If there was partial
response, a second course of 5FU was given 4 to 6 weeks following the completion
of the first course. As long as there was complete remission as shown by both
clinical and radiological examinations, the patient was placed merely under
observation. At the first sign of reactivation of disease another course of the
drug would immediately be prescribed. The interval between courses thus varied
from patient to patient.
For patients with " poor risk ", the 5 alternate daily doses were omitted.
Such patients had one of the following conditions (Ansfield et al., 1962)
1. Protein loss or impaired protein intake.
2. Extensive liver metastases.
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3. Intensive pelvic radiotherapy at any time preceding 5FU.
4. Extensive pelvic bone metastases.
5. Repeated courses of alkylating agents.
6. Previous adrenalectomy or hypophysectomy.
Of the 4 patients who were given palliative deep X-ray therapy at the same
time, only one had been given a smaller daily dose of 5FU than our standard.
Side effects
The various side effects and their respective frequencies are listed in Table II.
The majority ofpatients had marked anorexia but only slight nausea. Vomiting
occurred in only one patient, and this was controlled readily by anti-emetics.
TABLE II.-Side Effects
Number of Frequency
cases %
Anorexia and nausea . . . 22 . 91-6
Vomiting . . . . 1 . 4-2
Stomatitis . . . 8 . 33*3
Diarrhoea . . . . 2 . 8-3
Alopecia . . . . 4 . 16-6
Leucopenia
2000-3000 per cu. mm. . . 3 . 250
1000-2000 per cu. mm. . 3
Thrombocytopenia
less than 100,000 per cu. mm. . 2* . 8-3
Skin eruptions . . . . 3 12-5
? Drug death . . . . 1 . 4-2
Total 24
* One had excessive liver metastases, and the other a course ofdeep X-ray as well.
Stomatitis occurred in one-third of our cases. It took the form of clusters of
vesicles on the mucosal surface of the lower lip appearing within 10 days of the
commencement oftreatment. No frank mucosal ulceration had beenencountered,
as 5FU was discontinued in every case at the first sign of stomatitis. It served as
a valuable guide to the tolerance ofpatients to the drug and should be constantly
looked for during each course of treatment. Only 2 patients (8.3 per cent) had
diarrhoea in addition to stomatitis. This contrasted sharply with the high
incidence reported in the other series, e.g. 80 per cent by Curreri et al. (1958) and
64 per cent by Ansfield et al. (1962). Its low incidence in our series might be
accounted for by the timely withdrawal of 5FU, as had been the experience of
Wilson (1960).
Alopecia was encountered in 4 patients, but in only one of them could it be
considered excessive. However, we made it a point to forewarn every patient,
particularly female, of this possible complication.
Leucopenia was without exception only transient and usually found towards
the beginning of the third week of treatment. Only in a quarter of the patients
did the white cell count fall below 3000 per cu. mm. and in half of them it fell
below 2000. Of the 2 patients who had thrombocytopenia, one had deep X-ray
therapy in addition to 5FU, while the other had extensive liver metastases with
impairment of liver function before the treatment.
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One patient developed a dusky red erysipeloid skin eruption with a butterfly
configuration on the face. This subsided in one week despite continuation of
5FU. Another patient had erythematous papular skin eruptions over the chest
and proximal parts of the upper limbs on the 7th day of treatment. Because of
this, the treatment was suspended and the eruption subsided within a few days.
A second course was instituted after aninterval of6 weeks andthis time the patient
completed the course without any untoward reaction. A third patient developed
vesiculo-papular skin eruptions of a distribution similar to that of the second
patient shortly before her death half-way through the 5th course of treatment.
There was, however, no side effect of note observed during the earlier courses.
There was one death in this series of 24 " adequately " treated patients, which
might be accounted for by drug toxicity. This was the patient just referred to,
who had received 4 courses of 5FU with excellent objective response, but died
unexpectedly during her 5th course. The only sign of drug toxicity was the
skin eruptions. The blood picture remained within normal limits throughout.
Necropsy did not reveal the cause of death. Septicaemia and electrolyte im-
balance from diarrhoea or paralytic ileus had been reported to be the common
causes ofdeath, but these were not evident in this case. Our drug mortality rate
is, therefore, 1 in 24 (4-2 per cent). Using similar dose schedules, Weiss et al.
(1961) and Zubrod (1961) reported respectively rates of 6 per cent from 163
patients and 9 per cent from 287 patients.
Liver function and renal function tests were done routinely before and after
each course of 5FU. In no instance was there any evidence of impairment of
function of these two organs developing after the treatment when it was not
present before.
Results of treatment
The criteria of improvement suggested by Curreri et al. (1958) have been
adopted in the present clinical trial and they are as follows:-
1. A measurable reduction in tumour size including relief ofmechanical
obstruction.
2. General symptomatic improvement including an increase of appetite
and/or relief of pain.
3. Improvement of working capacity such as a partial to full return to
former activities.
4. Maintenance of or an increase in body weight.
5. The persistence of these signs of improvement for at least 2 months.
The most encouraging result was obtained with carcinoma of the breast. Out
of a total of 8 patients treated, 5 had good objective response for periods ranging
from 2 to 13 months. This compares favourably with other reported series in
which the response rates ranged from one-third to one-halfofthe patients treated.
The results obtained by different authors are tabulated in Table III. Cases 1, 2
and 4 are described below to illustrate the palliation that might be obtained in
breast carcinoma by the use of 5FU.
Case 1 (Fig. 1 to 6)-Female, aged 50. First seen on October 26, 1961, with
Stage IV carcinoma of breast with skin involvement wide of the affected breast.
A course of deep X-ray therapy was commenced on November 6, 1961. Only 2
weeks later the skin involvement had already spread across the midline to in-
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volve the opposite breast despite the treatment. Deep X-ray therapy was there-
fore discontinued, and stilboestrol in doses of 5 mg. t.i.d. was given instead, as
she had passed menopause 6 years ago. Good remission of her disease lasted for
8 months, after which there was recrudescence of the local condition with, in
addition, the appearance of pulmonary and skeletal metastases. Stilboestrol
was then discontinued. As there was no withdrawal remission after a period of
TABLE III.-Results of Treatment with 5-fluorouracil by tarious Authors
Objective response
Overall duration
Authors Year Neoplasm No. %
% of remission
Hoffmann-La 1960 . Ca. breast . 154 50 32-5
Roche Inc. Clinical
Data
Wilson . . 1960 . Ca. breast 6 2 33-3
Weiss, et al. . 1961 Ca. breast . 38 . 15 39 0 . 6 to more than 13
weeks
Kennedy & . 1961 Ca. breast . 43 . 18 42-0 . 2 to 6 months
Theologides
Hurley et al.. 1961 . Ca. breast . 82 42 51 0 . Average 6-8 months
Ansfield, etal. . 1962 . Ca. breast 158 52 32-5
Present series . 1963 . Ca. breast . 8 5 625 . 2 to 13 months
(average 7 8)
Ansfield, et al. . 1962 . All types 428 91 21-3 Average 9 months
Present series . 1963 . All types 21 8 38- 1 . 2 to 13 months
(average 6 5)
one month, 5FU therapy was instituted on October 17, 1962. Following this,
regression of the local disease as well as the metastases was noted. A second
course was given 4 weeks later for residual skin nodules. She put on 10 pounds
ofweight, and regained full working capacity. Subsequently, she received another
two courses, and when last seen 9 months after the completion of the first course
of 5FU therapy she was found to be free of symptoms. Throughout the treatment
no side effect has been noted.
Case 2 (Fig. 7 and 8)-Female, aged 44. A radical course of deep X-ray
therapy was given for Stage III (T3, NI, MO) carcinoma of the right breast on
September 16, 1959. She had complete remission for a period of 2 years after
which recurrence was detected. An attempt was made to control this by radiation-
induced menopause followed by androgen therapy. There was, however, no
response at all to this form of treatment. Consequently, 5FU therapy was com-
menced on June 27, 1962. She developed skin eruptions, stomatitis and diarrhoea
during the first course of treatment, but marked regression of the breast tumour
and skin nodules was noted 3 weeks from the commencement of treatment. A
EXPLANATION OF PLATES
FIG. 1.-Case 1 before 5FU. Arrows point to osteolytic metastasis in pubic bonc.
FIG. 2. Case 1 after 5FU. Osteolytic metastasis in pubic bone consolidating.
FIG. 3. Case 1 before 5FU. Arrows pointing at large rounded metastasis in left lung.
FIG. 4. Case 1 after 5FU. Metastasis much smaller.
FIG. 5. Case 1 before 5FU.
FIG. 6.-Case 1 after 5FU. Skin nodules partially regressed.
FIG. 7. Case 2 before 5FU.
FIG. 8.-Case 2 after 5FU. Skin involvement largely disappeared.
FIG. 9.-Case 4 before 5FU.
FIG.10. Case 4 after 5FU. Extensive skin involvement largely disappeared.
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second course of 5FU was given 6 weeks later for residual skin nodules, and
surprisingly this time she had no side effect apart from a transient leucopenia.
She subsequently received 2 more courses, and when last seen 13 months after
the first course, she was asymptomatic and had returned to her former activities.
Case 4 (Fig. 9 and 10)-Female, aged 66. Right radical mastectomy was
done on July 12, 1961, for Stage II carcinoma of the breast followed by post-
operative deep X-ray therapy on August 21, 1961. Half way through the course
of radiotherapy, skin nodules appeared wide of the treated region, and treatment
was therefore suspended on September 20, 1961. As she had passed menopause
13 years ago, she was put on stilboestrol therapy. Skin nodules progressed very
slowly for the following 10 months. These eventually escaped from the control of
stilboestrol and began to spread very rapidly. As no remission was observed one
month following the discontinuation of stilboestrol, 5FU was started on October
26, 1962. No side effect was encountered. Skin nodules began to regress at the
beginning of the second week of treatment and disappeared completely at the
end of the course after which she returned to her former activities. She received
2 further courses afterwards. The response to both was good but the duration
ofremission was progressively shorter each time. At the last follow-up 7 months
after the first course she was well.
According to the "Collected Clinical Data " published by Hoffmann-LaRoche
Inc. in 1960, the response rate of carcinoma of the uterine cervix to 5FU was 41
per cent (9 out of22 patients). Ansfield etal. (1962) reported an objective response
rate of 30 per cent (5 out of 17 patients). Of the 5 patients treated by us, only
2 responded, one subjectively, and the other objectively. It is interesting to note
that the patient who had objective response was suffering from adenocarcinoma
of the uterine cervix.
Our experience with adenocarcinoma of the uterine body had been more
encouraging than what was reported. Of the 2 patients treated with 5FU, one
had objective response, and the other subjective. The " Collected Clinical Data "
prepared by Hoffmann-LaRoche Inc. reported 2 with objective response out of
16 cases, whereas Ansfield et al. (1962) reported 1 out of 8.
Wilson (1960) reported excellent results with 5FUinthe treatment ofcarcinoma
of the urinary bladder producing 10 with objective response out of 12 cases. The
" Collected Clinical Data " recorded a response of52 per cent (16 out of 31 patients
treated). Ansfield et al. (1962), however, reported only 1 with objective response
out of 7 treated. We observed no objective response at all in 2 patients treated
with 5FU alone.
Results obtained with the other types of neoplasm are tabulated in Table I.
DISCUSSION
The size ofthe present series does not permit more than just some observations
to be made. If all the evaluable cases which had treatment by 5FU alone were
divided into those with adenocarcinoma and those with epidermoid carcinoma
irrespective of site, a distinctively better result could be observed in the former
group which had good objective response in 7 out of 12 cases (58.3 per cent) as
against 1 in 6 cases (16.6 per cent) in the latter. This is in agreement with the
findings of Schell and Cressy (1962) who reported a response rate of just over half
the cases in adenocarcinoma as against one-third in epidermoid carcinoma.
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TABLE IV.-Summaries of 24 Evaluable Cases
Previous
No. Diagnosis Sex/age treatment
1 . Ca. breast . F/50 . DXR &
hormone
2 . Ca. breast F/44 . DXR &
hormone
3 . Ca. breast . F/63 . Radical
mastect.,
DXR &
hormone
4 . Ca. breast . F/66 . DXR &
hormone
5 . Ca. breast . F/36 . DXR
6 . Ca. breast . F/50 . Radical
mastect.,
DXR &
hormone
7 . Ca. breast . F/47 DXR &
hormone
8 . Ca. breast . F/48 . DXR &
hormone
9 . Adenoca. . F/52 . Radium & .
cervix uteri Wertheim's
hysterect.
10 . Epidermoid . F/39 . Radium &.
ca. cervix DXR
uteri
11 . Epidermoid
ca. cervix
12 . Epidermoid
ca. cervix
uteri
13 . Epidermoid
ca. cervix
uteri
14 . Ca. urinary
bladder
15 . Ca. urinary
bladder
16 . Ca. urinary
bladder
17 . Adenoca.
corpus
uteri
18 . Adenoca.
corpus
uteri
F/60 Radium &.
DXR
F/32 .
Total dose
& No. of
courses
19-5g.
Four
22-5 g.
Four
27-4 g.
Five
16-9g.
Three
3 0g.
One
7-1 g.
One
6-5 g.
One
6-75 g.
One
15-0 g.
Four
9-75g.
Two
4-25g.
Two
4- 85g.
One
f Condition before 5FU
and result
Skin nodules, lymph nodes,
pulmonary & bone meta-
stases all regressed. Living
and well
Rt. breast tumour, skin no-
dules & lymph nodes all re-
gressed. Living and well
Rt. cancer en cuirasse & Lt.
breast tumour both re-
gressed. Died during 5th
course
Rt. cancer en cuirasse & skin
nodules completely re-
gressed. Living & well
Considerable reduction in size
of enlarged liver with
marked improvement of
general condition. Died 3
months after treatment
Liver metastases, & skin no-
dules showed no response.
Died
Lt. cancer en cuirasse worse.
Died soon afterwards
Rt. cancer en cuirasse & nodal
metastases worse. Died
Vaginal tumour extension &
iliac nodal metastases re-
gressed. Died
Marked decrease in vaginal
discharge & bleeding. Died
Symptoms & signsworse. Died.
Symptoms & signs worse.
Died
F/32 . Radium &. 5- 75 g. . Symptoms &' signs worse.
DXR One Died
. M/45 .
. F/36 .
MI/41 P
cy
&
F/50 . u
& r
56-25g.
One
+ DXR
- . 56-25g.
One
+DXR
artial . 11 * 25 g.
,stect. Two
DXR
rgery . 3-75g.
adium One
+ DXR
F/61 . Surgery . 11
- 25 g.
radium Two
& DXR
Reduction in size of bladder
tumour with improvement
of urinary symptoms. Liv-
ing & well
Bladder tumour & pulmonary
metastases worse. Died
Temporary relief of pain, but
no objective response ob-
served. Died
Abdominal & pelvic lymph
nodes & pulmonary meta-
stases all showed marked
regression. Onlv pelvis
covered by DXR. Died
later of tumour dissemiina-
tion
Complete relief of pain &
vaginal bleeding & dis-
charge. Pelvic lesions static.
Died 4 months after treat
ment
Overall
duration of
Response remission
Objective . 9 months
Objective . 13 months
Objective 8 months
Objective . 7 months
Objective . 2 months
Nil
Nil
Nil
Objective 7 months
Subjective . 2 months
Nil
Nil
Nil
Objective . 4 months
Nil
Ni
Objective . 2 nionths
Subjective. 4 months
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TABLE IV.-continued.
No. Diagnosis Sex/age
19 Ca. ovary . F/44
20 . Ca. kidney
21 . Ca. naso-
pharynx
22 . Ca. nasal
cavity
(posterior
part)
23 . Adenoca
fallopian
tube
24 . Adenoca.
rectum
Previous
treatment
DXR
. M/54 .
Total dose
& No. of
courses
. 9-75g.
Two
5-65g.
One
+ DXR
Condition before 5FU
and result
Symptoms & signs unchanged
Living
Pelvic bone metastases re-
gressed partially. Died
F/36 DXR + . 325 g. Neck node irmetastases & peri-
cycloph- One nodal tumour infiltration
osphamide showed no response. Died
M/28 . - 565 g. . Nasal tumour, neck nodes and
One chest wall metastases
showed marked regression.
Died 2 weeks after comple-
tion of course.
F/49 . Surgery . 14-25 g. . Pelvierecurrence, skin&nodal
Two metastases showed marked
response. Lost to follow-up
F/75 6 --25 g. Rectal tumour & its vaginal
One extension allregressed. Lost
+ DXR to follow-up
Response
Nil
Overall
duration of
remission
. Objective . 3 months
Nil
. Objective
. Objective 4 months
. Objective . 2 months
One of the purposes of this clinical trial was to find out if there was any
difference in drug tolerance between European patients treated in Western
countries and Chinese patients in Hong Kong. The incidence of diarrhoea is
definitely lower in our patients, but, as has already been commented, this might
be the result of our routine discontinuation of the drug as soon as stomatitis was
detected.
It has been stated by several authors, (Curreri et al., 1958; Kennedy and
Theologides, 1961 ; Weiss et al., 1961) that tumour response was closely associated
with severe toxic reactions, but in our experience with Hong Kong Chinese patients
this was not invariable. Of the 8 patients who were treated with 5FU alone and
showed objective response only 3 had side effects worthy of note.
Ansfield et al. (1962) and many others gave theirpatients repeated maintenance
courses of 5FU at intervals of 4 to 6 weeks, even ifthere were no sign ofrecrudes-
cence of the disease, in the belief that a longer overall duration of remission and
survival might be achieved. We, on the other hand, adopted a policy of with-
holding a further course until there were signs of recrudescence if the previous
course had produced an apparently complete or optimum regression. We felt
that as long as there was nothing to palliate the patient should be spared not
only the toxic effects of the drug but also should be allowed to lead a life as close
to normal as his condition permitted. Repeated courses of treatment at such
short intervals would have inevitably upset his routine of life and made him feel
that the sword of Damocles was still hanging over him. Admittedly, the dura-
tions of remission after each course in our cases were also short-ranging from
9 to 4 months-but they were significantly longer than 4 to 6 weeks. The over-
all durations of remission in our total cases ranged from 2 to 13 months (average
= 6-5) and in cases with carcinoma of the breast 7-8 months. From Table III
it can be seen that these overall durations compare favourably with those reported
by other workers who employed a routine ofgiving repeated maintenance courses
at regular intervals. It is, therefore, felt that nothing is to be gained byemploying
5
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a more energetic method than our " watch and palliate " policy which gives
less disturbance to the patients.
SUMMARY
1. The current literature on the clinical application of 5FU has been briefly
reviewed.
2. The results of the treatment of 28 Hong Kong Chinese patients suffering
from various types of advanced solid cancers with 5FU alone or in combination
with deep X-rays were presented. Ofthe two types ofneoplasm, adenocarcinoma
and epidermoid carcinoma, objective response was observed in 58-3 per cent of
the former cases and 16-6 per cent in the latter.
3. Apart from marked anorexia, side effects were less frequently encountered
among Hong Kong Chinese patients than among European patients treated
elsewhere.
4. Objective response was not invariably associated with severe toxic reactions
among Chinese patients. Only 3 out of 8 patients with objective response had
side effects worthy of note.
5. If complete or optimum tumour regression has been achieved after a full
course of 5FU, a " watch and palliate " policy which gives less disturbance to the
patient is recommended in preference to the giving of repeated maintenance
courses at 4-6 weeks' interval.
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